Abstract
A withdrawal syndrome consisting of nervousness, palpitations, diaphoresis, and insomnia appeared in 3 patients within 16-48 hours following discontinuation of guanabenz, a new centrally acting antihypertensive agent. A similar syndrome of sympathetic overactivity has been described with abrupt withdrawal of clonidine. Three of 4 patients treated with 48 mg/day but none of 20 other patients treated with 32 mg/day or less guanabenz developed this syndrome. None of the 3 patients developed hypertensive crisis, though one had a modest rise in the blood pressure above baseline levels. It is concluded that guanabenz therapy should not be discontinued abruptly and that, when possible, the dosage should be limited to less than 48 mg/day.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 148-150 |
| Number of pages | 3 |
| Journal | Journal of Clinical Pharmacology |
| Volume | 19 |
| Issue number | 2-3 |
| State | Published - 1979 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Withdrawal syndrome following cessation of guanabenz therapy. / Ram, C. V S; Holland, B.; Fairchild, C.; Gomez-Sanchez, C. E.
In: Journal of Clinical Pharmacology, Vol. 19, No. 2-3, 1979, p. 148-150.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Withdrawal syndrome following cessation of guanabenz therapy
AU - Ram, C. V S
AU - Holland, B.
AU - Fairchild, C.
AU - Gomez-Sanchez, C. E.
PY - 1979
Y1 - 1979
N2 - A withdrawal syndrome consisting of nervousness, palpitations, diaphoresis, and insomnia appeared in 3 patients within 16-48 hours following discontinuation of guanabenz, a new centrally acting antihypertensive agent. A similar syndrome of sympathetic overactivity has been described with abrupt withdrawal of clonidine. Three of 4 patients treated with 48 mg/day but none of 20 other patients treated with 32 mg/day or less guanabenz developed this syndrome. None of the 3 patients developed hypertensive crisis, though one had a modest rise in the blood pressure above baseline levels. It is concluded that guanabenz therapy should not be discontinued abruptly and that, when possible, the dosage should be limited to less than 48 mg/day.
AB - A withdrawal syndrome consisting of nervousness, palpitations, diaphoresis, and insomnia appeared in 3 patients within 16-48 hours following discontinuation of guanabenz, a new centrally acting antihypertensive agent. A similar syndrome of sympathetic overactivity has been described with abrupt withdrawal of clonidine. Three of 4 patients treated with 48 mg/day but none of 20 other patients treated with 32 mg/day or less guanabenz developed this syndrome. None of the 3 patients developed hypertensive crisis, though one had a modest rise in the blood pressure above baseline levels. It is concluded that guanabenz therapy should not be discontinued abruptly and that, when possible, the dosage should be limited to less than 48 mg/day.
UR - http://www.scopus.com/inward/record.url?scp=0018408178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018408178&partnerID=8YFLogxK
M3 - Article
C2 - 422739
AN - SCOPUS:0018408178
VL - 19
SP - 148
EP - 150
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 2-3
ER -